scholarly journals A phenomenon of hypersensitivity to the diabetogenic effect of total RNA in rats that had alloxan diabetes

2020 ◽  
pp. 85-88
Author(s):  
Н.М. Геворкян ◽  
Н.В. Тишевская ◽  
А.Г. Бабаева
Keyword(s):  
Diabetes Mellitus ◽  
Body Weight ◽  
Blood Glucose ◽  
Alloxan Diabetes ◽  
Repeated Exposure ◽  
Lymphoid Cells ◽  
Female Rats ◽  
Diabetes Group ◽  
Total Rna ◽  
Intact Rats

Введение. Как было нами показано ранее, препараты аллогенных суммарных РНК лимфоидных и стволовых клеток способствуют нормализации уровня глюкозы в крови белых беспородных крыс со стойким аллоксановым диабетом. Цель исследования - оценка влияния суммарной РНК, выделенной из селезенки крыс с аллоксановым диабетом, на уровень глюкозы в крови интактных крыс и животных, перенесших стойкий аллоксановый диабет. Методика. Эксперимент выполнен на 34 белых беспородных крысах-самках массой 250-280 г.: 12 интактных животных составили «интактный контроль». У 22 животных моделировали аллоксановый диабет путем однократного подкожного (п/к) введения полного адъюванта Фрейнда (0,5 мл) и последующего подкожного введения аллоксана тригидрата (200 мг/кг) - группа «алоксановый диабет». Селезенка 10 крыс группы «аллоксановый диабет» была использована для получения суммарной РНК. У 12 крыс группы «аллоксановый диабет» уровень глюкозы в крови был стабильно нормализован введением суммарной РНК клеток костного мозга, селезенки и поджелудочной железы - группа «перенесшая диабет». На 45-е сут эксперимента 12 крыс группы «интактный контроль» и 12 крыс группы «перенесшей диабет» использованы в новом опыте (по протоколу «2-й этап работы»). У 6 животных группы «интактный контроль» (впервые) и у 6 животных группы «перенесший диабет» (повторно) моделировали аллоксановый диабет путем подкожного введения аллоксана в дозе 100 мг/кг. Оставшимся 6-ти животным группы «интактный контроль» и 6-ти животным группы «перенесших диабет» вводили внутрибрюшинно суммарную РНК (15 мкг/100 г веса тела), выделенную из селезенок 10 крыс группы «аллоксановый диабет. Результаты. Показано, что исследуемая суммарная РНК в дозе 15 мкг/100 г массы тела вызывала гипергликемию у всех подопытных животных, сравнимую с действием 600-700-кратной дозы самого аллоксана, при этом крысы, ранее перенесшие диабет, реагировали значимо сильнее. Повторный контакт с аллоксаном у крыс, перенесших ранее диабет, так же вызывал значимо более выраженную гипергликемию, чем реакция на аллоксан у интактных крыс. Заключение. Выявлен феномен диабетогенного действия исследуемой суммарной РНК, а также повышенную чувствительность животных, ранее перенесших аллоксановый диабет, к повторному действию повреждающего агента. Полученные эффекты свидетельствуют о принципиальной возможности использовать суммарную РНК лимфоидных клеток для создания моделей заболеваний человека и разработку новых подходов в области персонифицированной медицины. Introduction. As we have shown earlier, preparations of allogenic total RNA from lymphoid and stem cells contribute to normalization of blood glucose levels in white outbred rats with persistent alloxan-induced diabetes. The aim of this study was to evaluate the effect of total RNA from the spleen of rats with alloxan diabetes on blood glucose of intact and post-alloxan diabetic animals. Method. Experiments were performed on 34 white outbred female rats weighing 250-280 g. Rats were divided into intact animals (n=12) and rats with experimental alloxan diabetes mellitus (n=22). Diabetes mellitus was modeled by a single subcutaneous (s.c.) injection of complete Freund’s adjuvant (0.5 ml) followed by a s.c. injection of alloxan trihydrate (200 mg/kg). Spleens from 10 rats with alloxan diabetes were used for obtaining total RNA. In the remaining 12 rats with alloxan diabetes, the level of blood glucose was completely normalized by administration of total RNA from the bone marrow, spleen, and pancreas (post-diabetes group). On day 45 of this experiment, 12 intact rats and 12 post-diabetes rats were used for a new experiment (second stage protocol). Alloxan diabetes was induced in 6 intact rats (for the first time) and 6 post-diabetes rats (for the second time) by a s.c injection of alloxan 100 mg/kg. The remaining 6 rats of the intact control group and 6 rats of the post-diabetes group received an injection of total RNA (15 μg/100 g body weight, i.p.). Results. Administration of total RNA (15 μg/100 g body weight) induced hyperglycemia in all experimental animals, which was comparable with the effect of a 600-700-fold dose of alloxan. Rats that had previously had diabetes responded to the total RNA significantly stronger. Likewise, a repeated exposure to alloxan of post-diabetes rats induced significantly more pronounced hyperglycemia than the response to alloxan of intact rats. Conclusions. This study discovered a phenomenon of hypersensitivity to repeated exposure to alloxan and to the diabetogenic effect of total RNA in animals that had previously had alloxan diabetes. This effect suggests a possibility of using the total RNA of lymphoid cells to create animal models of human diseases and to develop new approaches in personalized medicine.

scholarly journals Paradoxical refractoriness developing with the allogeneic transfer of splenic lymphocyte total RNA from animals with treated alloxan diabetes to animals with untreated diabetes

2020 ◽  
pp. 37-46
Author(s):  
Н.М. Геворкян ◽  
Н.В. Тишевская ◽  
А.Г. Бабаева
Keyword(s):  
Diabetes Mellitus ◽  
Bone Marrow ◽  
Blood Glucose ◽  
Alloxan Diabetes ◽  
Diabetic Rats ◽  
Female Rats ◽  
Diabetes Group ◽  
Total Rna ◽  
Glucose Levels ◽  
Blood Glucose Levels

Ранее нами было показано, что препараты аллогенной суммарной РНК, выделенной из лимфоидных и стволовых клеток здоровых животных, вызывают нормализацию уровня глюкозы крови у крыс со стойким аллоксановым сахарным диабетом. Цель исследования -- выяснение влияния суммарной РНК лимфоцитов селезенки крыс, ранее перенесших стойкий аллоксановый диабет, на особенности течения эксперименального аллоксанового диабета у животных. Методика. Эксперимент выполнен на 35 белых беспородных крысах-самках массой 250-280 г: 5 интактных животных, 20 - с экспериментальным аллоксановым сахарным диабетом и 10 животных, ранее перенесших стойкий аллоксановый диабет, у которых уровень глюкозы крови был полностью нормализован введением суммарных РНК клеток костного мозга, селезенки и поджелудочной железы. Диабет у этих животных моделировали однократным подкожным введением полного адъюванта Фрейнда (0,5 мл на крысу) и последующим подкожным введением аллоксана тригидрата в дозе 200 мг/кг. Достигнутая нормогликемия у животных подтверждалась в течение последующих 60 сут. Из селезенок и костного мозга этих животных методом фенол-хлороформной экстракции была выделена суммарная РНК. На 20 крысах с экспериментальным аллоксановым сахарным диабетом изучали эффекты однократного внутрибрюшинного введения полученной суммарной РНК (15 мкг/100 г массы тела животного). Результаты. Обнаружено, что при введении суммарной РНК селезенки крыс, ранее перенесших аллоксановый диабет, животным с аллоксановым диабетом у последних развивалась стойкая и длительная рефрактерность к лечению терапевтическими препаратами РНК. Заключение. 1. Выявлен феномен повышенной чувствительности крыс с аллоксановым диабетом к действию суммарной РНК селезенки животных, ранее перенесших аллоксановый диабет. 2. Предполагаемой причиной рефрактерности является клональный компонент суммарной РНК CD8+ Т-лимфоцитов памяти из селезенки животных, ранее перенесших аллоксановый диабет. 3. Предполагается наличие механизма адресного взаимодействия отдельных компонентов суммарной РНК селезенки крыс, ранее перенесших аллоксановый диабет, с их лимфоцитами-мишенями в организме реципиентов с аллоксановым диабетом. Introduction. Earlier we have shown that preparations of allogenic total RNA from lymphoid and stem cells of healthy animals contribute to normalization of blood glucose levels in white outbred rats with persistent alloxan-induced diabetes mellitus. The aim of this study was to find out whether allogenic total RNA isolated from the spleen of rats treated for alloxan diabetes affects its course, as determined by changes in blood glucose, in animals with persistent alloxan diabetes. Methods. Experiments were performed on 35 white outbred female rats weighing 250-280 g. Rats were divided into intact animals (n=5), rats with experimental alloxan diabetes mellitus (n=20), and rats after persistent alloxan diabetes (n=10) whose blood glucose level had been completely normalized by administrating total RNA of bone marrow, splenic, and pancreatic cells (post-diabetes group). Diabetes mellitus was modeled with a single subcutaneous (s.c.) injection of complete Freund’s adjuvant (0.5 ml) followed by a s.c. injection of alloxan trihydrate (200 mg/kg). Achievement of normoglycemia in animals of the post-diabetes group was confirmed over the next 60 days. Then total RNA was isolated from their spleen and bone marrow by phenol-chloroform extraction, and the effect of a single intraperitoneal injection of total RNA (15 μg/100 g body weight) was studied. Results. Administration of splenic total RNA from rats previously treated for alloxan diabetes to animals with alloxan diabetes resulted in development of stable and prolonged refractoriness of diabetic rats to the treatment with therapeutic RNA preparations [11]. Conclusions. This study discovered a phenomenon of hypersensitivity of rats with alloxan diabetes to the diabetogenic effect of total RNA from animals that had previously had alloxan diabetes. Apparently, this refractoriness was caused by the clonal component of the total RNA of CD8 + T memory lymphocytes from the spleen of post-diabetes animals. A mechanism is proposed for the interaction between individual components of splenic total RNA from post-diabetes rats and their target lymphocytes in recipients with alloxan diabetes.

The role of lymphoid and stem cell total rnas in correсtion of blood glucose level in experimental diabetes mellitus

2019 ◽  
pp. 88-95
Author(s):  
Н.М. Геворкян ◽  
Н.В. Тишевская ◽  
А.Г. Бабаева
Keyword(s):  
Diabetes Mellitus ◽  
Stem Cells ◽  
Bone Marrow ◽  
Body Weight ◽  
Blood Glucose ◽  
Blood Glucose Level ◽  
Glucose Level ◽  
Rna Isolation ◽  
Peripheral Blood Lymphocytes ◽  
Lymphoid Cells

Цель - оценка влияния препаратов суммарной РНК лимфоидных клеток на уровень глюкозы в крови при экспериментальном аллоксановом диабете. Методика. Работа выполнена на 68 белых беспородных крысах обоего пола массой 180-220 г. Для моделирования аллоксанового сахарного диабета 1 типа животным однократно подкожно вводили полный адъювант Фрейнда в дозе 0,5 мл/крысу. Через 24 ч (на фоне 24-часового голодания, при свободном доступе к воде) однократно подкожно вводили препарат аллоксан тригидрат («La Chema», Чехия) в дозе 200 мг/кг (4% раствор в 0,9% NaCl). Для предотвращения фатального кетоацидоза, начиная с 3-х сут после введения аллоксана, все крысы получали базисную инсулинотерапию. В экспериментах использовано 8 разновидностей препаратов суммарной РНК: из лимфоидных клеток селезенки, из костного мозга и хвостовой части поджелудочной железы интактных крыс (РНКс-1, РНКкм-1 и РНКп/ж, соответственно); из лимфоидных клеток селезенки крыс, подвергнутых кровопусканию в объеме 2% от массы тела за 17 ч до выделения РНК (РНКс-2 с индуцированной повышенной морфогенетической активностью); из лимфоидных клеток селезенки и тимуса крыс, подвергнутых кровопусканию в объеме 2% от массы тела за 96 ч до выделения РНК (РНКс-3 и РНКт-3, соответственно, с высокой ингибирующей морфогенез активностью); из лимфоцитов периферической крови здорового человека (РНКлпкч), а также из стволовых клеток стромы пупочного канатика человека. Результаты. Показана возможность восстановления функции инсулярного аппарата и стойкой нормализации уровня глюкозы в крови крыс с экспериментальным аллоксановым диабетом 1 типа. Установлено наличие корригирующей способности аллогенных и ксеногенных препаратов суммарной РНК, выделенной из лимфоидных органов крыс и лимфоцитов периферической крови человека, а также из мезенхимных стромальных клеток пуповины человека, в отношении уровня глюкозы крови у крыс. Продемонстрирован различный вклад препаратов суммарной РНК, полученной из разных лимфоидных органов и стволовых клеток, в восстановлении нормального уровня глюкозы в крови животных. Установлено, что указанные препараты действуют на разные ткани-мишени в процессе восстановления функции инсулярного аппарата. Заключение. Полученные данные свидетельствуют о принципиальной возможности эффективного лечения сахарного диабета 1 и 2 типов. Доказана эффективность неинвазивного интраназального введения аллогенных и ксеногенных препаратов суммарной РНК лимфоидных и стволовых клеток. Полученные результаты ставят вопрос о необходимости разработки более адекватной экспериментальной модели, а также о перспективности поиска подходов к персонифицированному индивидуальному лечению этой патологии с учетом особенностей ее развития в каждом конкретном случае. Aim. To study the effect of total RNA from lymphoid cells on blood glucose in experimental alloxan diabetes mellitus (DM). Methods. The study was conducted on 68 white mongrel rats of both sexes weighing 180-220 g. Alloxan DM was modeled with full Freund’s adjuvant (0.5 ml/rat). After 24 h of fasting with free access to water, a single dose of alloxan trihydrate (La Chemas, Czeck Republic) was injected subcutaneously (200 mg/kg as a 4% solution in saline). All rats received basis insulin therapy starting from day 3 of the alloxan injection to prevent fatal ketoacidosis. Eight types of total RNA were used: from splenic lymphoid cells, bone marrow, and caudal part of the pancreas of intact rats; from splenic lymphoid cells of rats after blood withdrawal (2% of body weight 17 h prior to RNA isolation) (RNA after induction of increased morphogenetic activity); from splenic and thymic lymphoid cells of rats after blood withdrawal (2% of body weight 96 h prior to RNA isolation) (RNAs with high morphogenesis-inhibiting activity); and from peripheral blood lymphocytes and umbilical cord stromal stem cells of a healthy human. Results. The study showed a possibility for functional recovery of the insular apparatus and stable normalization of blood glucose level in rats with experimental alloxan DM, a model of clinical type 1 DM. Allogenic and xenogeneic total RNAs isolated from rat lymphoid organs, peripheral blood lymphocytes, and mesenchymal stromal cells of human umbilical cord were able to correct the blood glucose level in rats. Total RNAs isolated from different lymphoid organs and stem cells differently contributed to normalization of blood glucose in rats. These total RNAs were shown to influence different target tissues during restoration of the insular apparatus function. Conclusion. The study showed a principle possibility of effective therapy for types 1 and 2 DM and demonstrated the efficacy of non-invasive intranasal administration of allogenic and xenogeneic total RNAs from lymphoid and stem cells. These results indicated a need for developing a more relevant experimental model and offered a promising outlook for individualized treatment of this disease with due account of its peculiar features in each specific case. The study was conducted as a part of the Program for Basic Research of State Academies of Science in 2013-2020 on Development of Cell Models for Molecular Processes in Organs and Tissue (V.N. Orekhovich Research Institute of Biomedical Chemistry) and the complex Research Work #01201354257 on Regulation of Hemopoietic and Nonhemopoietic Functions of Bone Marrow Cells in Experiment and Clinic (Sounth Ural State Medical University).

scholarly journals Pharmaceutical hit of anti type 2 Diabetes mellitus on the phenolic extract of Malaka (Phyllanthus emblica L.) flesh

2019 ◽  
Vol 5 (1) ◽  
Author(s):  
Musri Musman ◽  
Mauli Zakia ◽  
Ratu Fazlia Inda Rahmayani ◽  
Erlidawati Erlidawati ◽  
Safrida Safrida
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Body Weight ◽  
Blood Glucose ◽  
Phyllanthus Emblica ◽  
Glucose Levels ◽  
Blood Glucose Levels ◽  
Phenolic Extract

Abstract Background Ethnobotany knowledge in a community has shaped local wisdom in utilizing plants to treat diseases, such as the use of Malaka (Phyllanthus emblica) flesh to treat type 2 diabetes. This study presented evidence that the phenolic extract of the Malaka flesh could reduce blood sugar levels in the diabetic induced rats. Methods The phenolic extract of the P. emblica was administrated to the glucose-induced rats of the Wistar strain Rattus norvegicus for 14 days of treatment where the Metformin was used as a positive control. The data generated were analyzed by the two-way ANOVA Software related to the blood glucose level and by SAS Software related to the histopathological studies at a significant 95% confidence. Results The phenolic extract with concentrations of 100 and 200 mg/kg body weight could reduce blood glucose levels in diabetic rats. The post hoc Dunnet test showed that the administration of the extract to the rats with a concentration of 100 mg/kg body weight demonstrated a very significant decrease in blood glucose levels and repaired damaged cells better than administering the extract at a concentration of 200 mg/kg weight body. Conclusion The evidence indicated that the phenolic extract of the Malaka flesh can be utilized as anti type 2 Diabetes mellitus without damaging other organs.

scholarly journals Oleuropein alleviates gestational diabetes mellitus by activating AMPK signaling

2020 ◽  
Author(s):  
Zhiwei Zhang ◽  
Hui Zhao ◽  
Aixia Wang
Keyword(s):  
Oxidative Stress ◽  
Diabetes Mellitus ◽  
Body Weight ◽  
Blood Glucose ◽  
Gestational Diabetes ◽  
Gestational Diabetes Mellitus ◽  
Signaling Pathway ◽  
Hepatic Glycogen ◽  
Ampk Signaling ◽  
Tnf Α

Background: Gestational diabetes mellitus (GDM) has a high incidence rate among pregnant women. The objective of the study was to assess the effect of plant-derived oleuropein in attenuating inflammatory and oxidative stress of GDM. Methods: Oleuropein was administered to GDM mice at the doses of 5 or 10 mg/kg/day. Body weight, blood glucose, insulin and hepatic glycogen levels were recorded. To evaluate the effect of oleuropein in reducing oxidative stress, enzyme-linked immunosorbent assay (ELISA) was used to measure the hepatic oxidative stress markers. The inflammation levels of GDM mice were evaluated by measuring serum levels of IL-6 and TNF-α by ELISA, and mRNA levels of IL-1β, TNF-α and IL-6 by real-time PCR (RT-PCR). The AMP-activated protein kinase (AMPK) signaling pathway was assessed by Western blot. Gestational outcome was analyzed through comparing litter size and birth weight. Results: Oleuropein attenuated the elevated body weight of GDM mice, and efficiently reduced blood glucose, insulin and hepatic glycogen levels. Oxidative stress and inflammation were alleviated by oleuropein treatment. The AMPK signaling was activated by oleuropein in GDM mice. Gestational outcome was markedly improved by oleuropein treatment. Conclusions: Our study suggests that oleuropein is effective in alleviating symptoms of GDM and improving gestational outcome in the mouse model. This effect is achieved by attenuating oxidative stress and inflammation, which is mediated by the activation of the AMPK signaling pathway.

SEX DIFFERENCES OF CARBOHYDRATE AND LIPID METABOLISM IMPAIRMENT IN RATS WITH TYPE 2 DIABETES MELLITUS

2018 ◽  
Vol 64 (2) ◽  
pp. 39-45 ◽  
Author(s):  
Nataliia Gorbenko ◽  
Oleksii Borikov ◽  
Olha Ivanova ◽  
K. V. Taran ◽  
T. S. Litvinova ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Body Weight ◽  
Lipid Metabolism ◽  
Female Rats ◽  
Glucose And Lipid Metabolism ◽  
Carbohydrate And Lipid Metabolism ◽  
Lipid Metabolism Disorders

A sex difference of carbohydrate and lipid metabolism disorders in rats with type 2 diabetes has been studied. It was established that type 2 diabetes leads to a more pronounced deterioration in carbohydrate toleranceand insulin sensitivity in males compared to female rats, but the sex doesn’t affect basal glycemia and fructosamine levels. It was found that the increase of body weight and visceral fat in rats with type 2 diabetes is moremanifested in females than in males. It has been determined that hypertriglyceridemia is higher in diabeticmales compared to diabetic females, and the level of common lipids in the liver, both intact females and femaleswith type 2 diabetes, is lower than that of the males. The obtained results indicate a more expressive impairment of glucose and lipid metabolism in males compared to females with type 2 diabetes

Effect of Crude Leaves Extract of Bersama Abyssinica on Blood Glucose Level and Serum Lipid Level of Streptozotocin-Induced Diabetic Mice: Evidence for In vivo Antidiabetic Activity

2021 ◽  
Vol 19 ◽  
Author(s):  
Zemene Demelash Kifle ◽  
Agumas Alemu Alehegn ◽  
Baye Yrga Adugna ◽  
Abebe Basazn Mekuria ◽  
Engidaw Fentahun Enyew
Keyword(s):  
Diabetes Mellitus ◽  
Body Weight ◽  
Blood Glucose ◽  
Serum Lipid ◽  
Lipid Level ◽  
Serum Lipid Level ◽  
Diabetic Mice ◽  
Lipid Levels ◽  
Antidiabetic Effect ◽  
Bersama Abyssinica

Background: Diabetes mellitus is one of the major and common metabolic, and chronic disorders in the world. Several medicinal plants have been used globally for the management of diabetes mellitus. The current study aimed to study the anti-hyperglycemic and anti-hyperlipidemic effects of Bersama abyssinica. Methods: Antidiabetic effect of 80% methanolic crude extract of Bersama abyssinica was studied in repeated dose-treated STZ-induced diabetic mice model. The activities of Bersama abyssinica on serum lipid level and body weight were investigated on STZ-induced diabetic mice. Data were analyzed using one-way ANOVA and significant when the p-value was less than 0.05. Results: All doses of the crude 80% methanolic extract of Bersama abyssinica (100 mg/kg, 200 mg/kg, and 400 mg/kg) exhibited a noticeable BGL reduction when compared with baseline blood glucose level and diabetic control on the 7th and 14th days of administration. Moreover, the higher dose of the extract (at 400 mg/kg) significantly (p < 0.001, 54.3%) decreased the BGL in STZ-induced diabetic mice. The maximum decrement in fasting BGL was achieved at the 14th days: 34.92%, 41.10%, 54.30%, and 59.66%, respectively for BAC 100 mg/kg, BAC 200 mg/kg, BAC 400 mg/kg, and GLC 5 mg/kg treated groups. Bersama abyssinica also displayed a significant (p < 0.05) improvement of serum lipid levels and body weight. Conclusion: Bersama abyssinica crude extract exhibited a significant antidiabetic effect and prevented body weight loss in streptozotocin-induced diabetic mice. The finding also confirmed the valuable biochemical activity of Bersama abyssinica by improving serum lipid levels.

scholarly journals Impact of different omega-3 fatty acid sources on lipid, hormonal, blood glucose, weight gain and histopathological damages profile in PCOS rat model

2020 ◽  
Vol 18 (1) ◽  
Author(s):  
Fiza Komal ◽  
Muhammad Kamran Khan ◽  
Muhammad Imran ◽  
Muhammad Haseeb Ahmad ◽  
Haseeb Anwar ◽  
...  
Keyword(s):  
Body Weight ◽  
Weight Gain ◽  
Blood Glucose ◽  
Fish Oil ◽  
Lipid Profile ◽  
Nutrient Digestibility ◽  
Female Rats ◽  
Omega 3 ◽  
Hormonal Profile ◽  
Epa And Dha

Abstract Background Omega-3 fatty acids (Ω-3 PUFAs) may help to improve health status in polycystic ovarian syndrome (PCOS) by reducing numerous metabolic disorders (insulin sensitivity, hyperinsulinemia, lipid profile, obesity and inflammation). To evaluate the current objective, 16 weeks (6 weeks of adjustment period followed by 10 weeks of collection period) research trial was planned to check the impact of different sources of Ω-3 PUFAs (synthetic Ω-3, flaxseed and fish oil) on nutrient digestibility, weight gain, productive (lipid profile, glucose and insulin), reproductive profile (progesterone, follicle stimulating hormone (FSH), estrogen, luteinizing hormone (LH) and prolactin) and histological study of ovarian tissues in Wistar female rats. Methods Forty-five rats of 130 ± 10 g weight were divided into 5 groups, each having 9 rats: NC (negative control without PCOS), PC (positive control with PCOS), SO (synthetic omega-3 containing ALA, EPA and DHA), FO (flaxseed oil) and F (fish oil) fed at 300 mg/kg/orally/daily of these sources were added in the basal diets while PC and NC received only the basal diet. Food and water were offered ad libitum. PCOS was induced in the rats fed of PC, SO, FO and F diets group by single intramuscular injection of estradiol-valerate (4 mg/rat/IM). Body weight and blood glucose was recorded weekly. At 16th week of trial, blood samples were collected for lipid and hormonal analysis. Ovarian tissues were removed for pathological evaluation. Digestibility was measured by total collection method. Results Cholesterol, triglycerides and low-density lipoproteins were reduced in SO, FO and F groups when compared with rats of PC group. However, increasing trend of high-density lipoprotein (HDL) was found in same groups. The highest HDL (36.83 ± 0.72 mg/dL) was observed in rats fed F diet. In case of a hormonal profile, testosterone, LH and insulin levels showed a significant reduction after treatments. Blood glucose results showed significantly reducing trend in all the rats fed with Ω-3 PUFAs sources than PC from 5 to 10th week of trial. However, similar trend was noticed in rat’s body weight at the end of 6th week. In ovarian morphology, different stages of follicles were observed in groups fed SO, FO and F diets. Nutrient digestibility in PCOS induced rats was remained non-significant. Conclusions The three sources of Ω-3 PUFAs had effective role in improving lipid and hormonal profile, reducing blood glucose, weight gain and histopathological damages in PCOS rats. However, fish oil source might be an innovative approach to cure PCOS via reducing the weight and metabolic anomalies due to EPA and DHA.

The Effect of Biochanin A as PPAR γ agonist on LDL Particles Diameter and Type 2 Diabetic Dyslipidemia

2019 ◽  
Author(s):  
Darya Ghadimi ◽  
Mohammad Taghi Taghi Goodarzi ◽  
Mahdi Bahmani ◽  
Zohre Khajehahmadi
Keyword(s):  
Diabetes Mellitus ◽  
Body Weight ◽  
Blood Glucose ◽  
Fasting Blood Glucose ◽  
Male Rats ◽  
Biochanin A ◽  
Diabetic Patients ◽  
Low Density ◽  
Diabetic Dyslipidemia ◽  
Ldl Particles

Background and Aims: Small dense  low-density lipoproteins (sd-LDL) particles are smaller and heavier than typical LDL ones. They can penetrate into the endothelium of coronary arteries more easily because of their small size. Diabetes mellitus is accompanied by dyslipidemia such as increasing concentration of plasma very low density lipoprotein and sd-LDL. Peroxisome proliferator activated receptor γ (PPARγ ) can decrease the level of sd-LDL in plasma. Biochanin A (BCA), a natural compound, is a PPARγ agonist. The present study was designed to investigate the effect of BCA on sd-LDL-Clolesterol level in diabetic animals. Materials and Methods: Adult male rats (Wistar strain) were used as the animal models in this study. Animals were made diabetic by single intraperitoneal injection of Streptozotocin- Nicotinamide and then treated by 1 and 5 mg/kg of BCA for 28 days. Body weight and fasting blood glucose were also tested before and at the end of treatment. Furthermore, the size of LDL particles were measured by nondenaturing polyacrylamide gradient gel electrophoresis assay. Results: Results of the present study indicated that BCA administration at dose of 5mg/kg decreased fasting blood glucose level and increased body weight and diameter of LDL particles in diabetic animals significantly. Conclusions: BCA seems to be an appropriate agent in diabetes mellitus, because it improves the diabetic dyslipidemia, which is the most important complication in diabetic patients.

scholarly journals Effects of Encapsulated Propolis on Blood Glycemic Control, Lipid Metabolism, and Insulin Resistance in Type 2 Diabetes Mellitus Rats

2012 ◽  
Vol 2012 ◽  
pp. 1-8 ◽  
Author(s):  
Yajing Li ◽  
Minli Chen ◽  
Hongzhuan Xuan ◽  
Fuliang Hu
Keyword(s):  
Diabetes Mellitus ◽  
Insulin Resistance ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Body Weight ◽  
Lipid Metabolism ◽  
Blood Glucose ◽  
Glycemic Control ◽  
Density Lipoprotein

The present study investigates the encapsulated propolis on blood glycemic control, lipid metabolism, and insulin resistance in type 2 diabetes mellitus (T2DM) rats. The animal characteristics and biological assays of body weight, fasting blood glucose (FBG), fasting serum insulin (FINS), insulin act index (IAI), triglycerides (TG), total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C) were measured and euglycemic hyperinsulinemic glucose clamp technique were used to determine these effects. Our findings show that oral administration of encapsulated propolis can significantly inhibit the increasing of FBG and TG in T2DM rats and can improve IAI and M value in euglycemic hyperinsulinemic clamp experiment. There was no significant effects on body weight, TC, HDL-C, and LDL-C in T2DM rats treated with encapsulated propolis. In conclusion, the results indicate that encapsulated propolis can control blood glucose, modulate lipid metabolism, and improve the insulin sensitivity in T2DM rats.

Sign in / Sign up

Export Citation Format

Share Document